Shopping Cart
- Remove All
- Your shopping cart is currently empty
BT-GSI, a γ-secretase inhibitor (GSI) with bone-targeting capabilities, effectively inhibits Notch signaling. Exhibiting dual action, it possesses both anti-myeloma and anti-resorptive properties, making it a promising candidate for research into multiple myeloma and related bone diseases. Additionally, BT-GSI demonstrates potential in inhibiting tumor growth and the progression of osteolytic disease.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $1,970 | 8-10 weeks | |
50 mg | $2,580 | 8-10 weeks | |
100 mg | $3,400 | 8-10 weeks |
Description | BT-GSI, a γ-secretase inhibitor (GSI) with bone-targeting capabilities, effectively inhibits Notch signaling. Exhibiting dual action, it possesses both anti-myeloma and anti-resorptive properties, making it a promising candidate for research into multiple myeloma and related bone diseases. Additionally, BT-GSI demonstrates potential in inhibiting tumor growth and the progression of osteolytic disease. |
Molecular Weight | 730.52 |
Formula | C26H46BrN5O10P2 |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.